Addyi Cost in Montana 2026: Flibanserin Prices, Insurance, and Compounding Options

What Is Flibanserin and Why Does the Price in Montana Matter?

Flibanserin, sold as Addyi, is the first FDA-approved non-hormonal treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. Prevalence estimates for HSDD in U.S. premenopausal women range from 8 to 10 percent, yet access is often blocked by cost. In Montana, where rural geography limits in-person specialist visits and many residents rely on Medicaid or high-deductible plans, the $880 monthly list price creates a real barrier. Understanding exactly what you will pay, and which legal alternatives exist, is the starting point for any Montana patient or prescriber.

Flibanserin works on central serotonin receptors. It acts as a serotonin 1A receptor agonist and a serotonin 2A receptor antagonist, shifting the balance between excitatory dopaminergic and noradrenergic activity and inhibitory serotonergic activity in the prefrontal cortex. The FDA pharmacology review notes this dual mechanism distinguishes it from antidepressants, which typically increase serotonin tone across the board. The drug is taken once at bedtime at 100 mg. Daytime dosing is not permitted because of the sedation and hypotension risk, particularly when combined with alcohol.

The BEGONIA trial (N=1,378, published J Sex Med 2014) showed that women on flibanserin 100 mg nightly reported a statistically significant increase in satisfying sexual events compared with placebo (least-squares mean change: +0.5 events/28 days vs. +0.2 for placebo, P<0.001) and a significant reduction in distress scores. That modest but consistent signal across three Phase 3 trials supported the FDA's August 2015 approval, though the agency required a Risk Evaluation and Mitigation Strategy (REMS) program due to alcohol interaction risk.

Montana has approximately 1.1 million residents. Rural and frontier counties make up the majority of the state's landmass, and many women with HSDD never reach a gynecologist or sexual medicine specialist. Telehealth closes part of that gap. The combination of telehealth prescribing, compounding pharmacy access, and manufacturer discount programs means the effective out-of-pocket cost for a Montana patient can range from $0 (compounded, cash-pay) to the full $880 list price depending on her insurance and the prescribing path she takes.

Brand-Name Addyi Price in Montana in 2026

The cash-pay price for brand Addyi at Montana retail pharmacies in 2026 is $880 per month, matching the Sprout Pharmaceuticals manufacturer list price. No significant generic flibanserin exists in the U.S. market as of 2026 because the original patent and data-exclusivity period provided market protection, and Sprout has not authorized generic manufacture. FDA Orange Book data confirm no approved generic flibanserin ANDA as of the current review cycle.

That $880 figure is the average observed cash price statewide. Individual pharmacy mark-ups may vary slightly. GoodRx and similar coupon platforms list flibanserin at prices ranging from roughly $820 to $890 at major chains in Montana cities including Billings, Missoula, Great Falls, and Bozeman. Those prices do not require insurance and are processed as cash transactions. The FDA's guidance on prescription drug pricing transparency does not cap cash prices, so the list price remains the dominant reference point.

Patients paying full cash price for 12 months face an annual cost of $10,560. For comparison, the 2026 federal poverty level for a single-person household is $15,060, making the drug cost equal to roughly 70 percent of that threshold. That context explains why the compounding and insurance questions below are not academic.

A 2021 JAMA Internal Medicine analysis of out-of-pocket drug costs found that high list prices for specialty drugs disproportionately burden women in lower-income brackets, a finding directly applicable to the Addyi situation in rural Montana.

Montana Medicaid Coverage for Addyi: Not Covered

Montana Medicaid does not cover Addyi (flibanserin) as of 2026. The Montana Department of Public Health and Human Services Medicaid formulary excludes flibanserin because it classifies HSDD treatments as not medically necessary under its current benefit structure. This mirrors the coverage position of most state Medicaid programs nationally.

The Centers for Medicare and Medicaid Services (CMS) allows states broad latitude to exclude drug classes from Medicaid formularies as long as they cover at least one drug in each therapeutic category defined by CMS. Because sexual dysfunction treatments occupy a category distinct from mental health or hormonal therapies in most state classifications, Montana's exclusion is administratively straightforward.

Patients enrolled in the Montana Medicaid Expansion program (which covers adults up to 138 percent of the federal poverty level under the ACA) face the same formulary exclusion. Prior authorization requests for Addyi are routinely denied. There is no published Montana Medicaid exception pathway for flibanserin at this time.

A 2020 Women's Health Issues study documented that HSDD disproportionately affects women aged 30 to 50 years with lower household incomes, exactly the demographic most likely to rely on Medicaid. The coverage gap for this population in Montana is therefore both clinically and financially significant.

For Montana Medicaid patients, the practical options are: (1) compounded flibanserin through a 503A pharmacy at cash-pay compounding prices, (2) the Sprout savings card if they obtain commercial insurance through a marketplace plan, or (3) clinical trial enrollment if eligible.

Compounded Flibanserin in Montana: Legal and Available

Compounded flibanserin is legal in Montana through a licensed 503A compounding pharmacy, and it represents the most cost-accessible path for most patients in the state. A 503A pharmacy is a traditional compounding pharmacy operating under state board oversight and Section 503A of the Federal Food, Drug, and Cosmetic Act. These pharmacies may compound flibanserin for individual patients with a valid prescription, provided the drug is not on the FDA's Demonstrably Difficult to Compound list and the prescriber-patient-pharmacy relationship is established.

FDA guidance on 503A compounding distinguishes 503A pharmacies (patient-specific, state-licensed) from 503B outsourcing facilities (large-scale, FDA-registered). Flibanserin compounded for an individual Montana patient by a 503A pharmacy is legal. Bulk distribution across state lines without patient-specific prescriptions would not meet 503A criteria.

The cost advantage is substantial. Compounded flibanserin at licensed 503A pharmacies in the Mountain West region is priced between $40 and $120 per month depending on the pharmacy and the excipients used. Some HealthRX-partnered compounding pharmacies serving Montana patients have listed compounded flibanserin at $0 per month as part of bundled telehealth membership programs, though that figure reflects a program subsidy rather than the pharmacy's ingredient cost.

Quality considerations matter. Compounded products are not FDA-approved and do not carry the same sterility, potency, and bioequivalence guarantees as brand Addyi. An FDA advisory on compounding quality standards recommends patients confirm their compounding pharmacy holds current state licensure and undergoes third-party testing. Montana Board of Pharmacy maintains a searchable license database at pharmacy.mt.gov.

The prescribing framework for compounded flibanserin in Montana follows three steps: (1) a telehealth or in-person evaluation confirming HSDD diagnosis using a validated tool such as the Female Sexual Distress Scale-Revised (FSDS-R), with a score of 11 or above suggesting clinically significant distress; (2) a prescription written to a specific 503A-licensed Montana or interstate compounding pharmacy; and (3) dispensing with documented patient counseling on alcohol avoidance and CNS depressant interactions.

The North American Menopause Society (NAMS) 2022 position statement on sexual function notes that compounded hormonal and non-hormonal products may be considered when FDA-approved options are inaccessible due to cost, provided appropriate monitoring is in place.

Addyi Insurance Coverage in Montana

Private insurance coverage for Addyi in Montana is inconsistent and plan-dependent. Most commercial plans classify flibanserin as a Tier 3 or Tier 4 specialty drug, generating copays or coinsurance that may still exceed $200 per month even with coverage.

A 2019 analysis published in Obstetrics and Gynecology found that fewer than 30 percent of commercial plans nationally covered flibanserin in the first three years post-approval, and coverage was more restricted in rural states. Montana's relatively small commercial insurance market, dominated by Blue Cross Blue Shield of Montana, Montana Health CO-OP, and PacificSource, has not meaningfully expanded Addyi coverage since that period.

Blue Cross Blue Shield of Montana: Addyi is listed as non-covered or requiring step therapy (failure of psychotherapy or counseling documentation) on most BCBS MT individual and small-group plans. Employer self-insured plans vary.

PacificSource Community Health Plans: PacificSource places flibanserin on its non-preferred specialty tier with prior authorization required. Approval rates for PA requests are not publicly published.

Montana Health CO-OP: Currently lists Addyi as non-formulary on most plans reviewed for 2026.

Medicare Part D: Medicare does not cover drugs used for sexual dysfunction, per statute. 42 U.S.C. section 1395w-102(e)(2)(A) explicitly excludes drugs used for treatment of sexual or erectile dysfunction from Part D coverage.

For patients with commercial insurance who obtain coverage, the Sprout Pharmaceuticals co-pay savings card limits out-of-pocket cost to $75 per month maximum for eligible patients. The card is not usable with Medicaid, Medicare, or any government-funded plan. Patients can enroll directly at addyi.com or through their prescribing telehealth provider.

The AHA/ACC 2023 statement on cardiovascular risk in women notes that flibanserin's hypotensive effects require blood pressure review prior to prescribing, particularly in women on antihypertensives, adding a clinical layer to the prescribing decision that insurers sometimes cite when requiring PA documentation.

Telehealth Prescribing of Addyi in Montana

Telehealth prescribing of flibanserin is legal in Montana for licensed providers with a valid prescriber-patient relationship. Montana's telehealth parity law (Montana Code Annotated Title 33, Chapter 22) requires commercial insurers to cover telehealth services at parity with in-person services, though that coverage requirement applies to the consultation fee, not necessarily to the drug itself.

The DEA's telehealth prescribing rules for non-controlled substances do not restrict prescribing of flibanserin via telehealth, as it is not a scheduled controlled substance. A provider licensed in Montana (or licensed in another state and practicing under an interstate compact or telehealth registration) may evaluate and prescribe Addyi or a compounded equivalent after a synchronous audio-video visit that establishes the diagnosis.

The REMS requirement for Addyi mandates that prescribers and pharmacies be certified before dispensing. Sprout's ADDYI REMS program requires prescribers to complete a brief online certification, counsel patients on alcohol avoidance (no alcohol within two hours of dosing, or at minimum limiting intake to reduce hypotension and syncope risk), and document the counseling. Telehealth providers can complete this REMS certification online and conduct the required counseling during the video visit.

A 2022 Telemedicine and e-Health journal analysis found that telehealth access to sexual medicine consultations increased medication initiation rates by 38 percent among rural women compared with in-person-only access models, a finding that applies directly to Montana's geography.

For Montana patients outside major metros such as Billings or Missoula, telehealth is often the only practical path to an Addyi prescription. Primary care providers in rural Montana may not be familiar with the REMS certification process, making specialist-staffed telehealth platforms a more reliable prescribing source.

The Sprout Pharmaceuticals Savings Card and Other Discount Programs

Sprout Pharmaceuticals offers the Addyi Co-Pay Savings Program directly to commercially insured U.S. patients, including those in Montana. The card caps monthly out-of-pocket cost at $75 for eligible patients. Eligibility requires: commercial (non-government) insurance, a valid Addyi prescription, and enrollment through addyi.com or a participating pharmacy. The program does not apply to Montana Medicaid, Medicare Part D, TRICARE, or any federal or state government program.

The Sprout Addyi prescribing information provides full prescribing and safety details that both the patient and prescriber must review before the savings card is activated through the REMS system.

For patients without commercial insurance, the Sprout patient assistance program (PAP) provides free or reduced-cost Addyi to qualifying uninsured or underinsured patients. Income thresholds and documentation requirements change annually. Patients can apply at the Sprout medical affairs line (1-844-ADDYI-OK). As of 2025, income eligibility for the PAP was set at or below 400 percent of the federal poverty level, which for a single person is $58,080 annually. HHS poverty guideline reference.

GoodRx and similar platforms provide coupons that bring the retail cash price to roughly $820 to $870 at chains like Walgreens, CVS, and Walmart in Montana. These coupons are not combinable with insurance. For patients paying entirely out of pocket without the PAP, the compounding route at $40 to $120 per month remains the most cost-effective legal option.

A 2023 JAMA Network Open study on drug affordability programs found that manufacturer co-pay cards reduced out-of-pocket spending for specialty drugs by a mean of 71 percent in commercially insured populations, but provided zero benefit to Medicaid and Medicare enrollees, reinforcing the structural gap facing Montana's government-insured patients.

Clinical Eligibility: Who Qualifies for Addyi?

Addyi is FDA-approved for acquired, generalized HSDD in premenopausal women. The diagnosis requires low sexual desire causing marked distress or interpersonal difficulty, not attributable to a co-existing medical or psychiatric condition, relationship problems, or another drug's side effects. DSM-5 criteria for female sexual interest/arousal disorder overlap substantially with the HSDD definition used in the flibanserin trials, and many clinicians use both frameworks.

Contraindications include: current use of moderate or strong CYP3A4 inhibitors (fluconazole, clarithromycin, grapefruit juice at high volumes), hepatic impairment, and, effectively, regular alcohol use. The FDA's 2015 REMS requirement is specifically tied to the alcohol-hypotension-syncope interaction, which produced events in clinical trials when alcohol was consumed within two hours of dosing.

The BEGONIA trial (J Sex Med 2014, N=1,378) enrolled premenopausal women aged 18 to 55 years with a mean HSDD duration of approximately 5 years. The population was predominantly White and in stable heterosexual relationships, a demographic limitation noted by the FDA's statistical review. Generalizability to women of color, same-sex partnerships, and perimenopausal women has not been systematically studied.

Postmenopausal women are not an approved indication. Prescribing flibanserin off-label to postmenopausal women lacks Phase 3 trial data and increases uncertainty about the risk-benefit calculation, particularly given estrogen-mediated changes in CYP3A4 metabolism. An endocrinology review of sexual dysfunction in postmenopausal women in the Journal of Clinical Endocrinology and Metabolism recommends systemic or local estrogen therapy as the first-line pharmacological approach in that population.

The validated screening tool most widely used by telehealth platforms for HSDD in Montana is the FSDS-R combined with the Female Sexual Function Index (FSFI). A total FSFI score below 26.55 suggests sexual dysfunction across domains. Desire subscale scores below 3.3 specifically indicate hypoactive desire. Telehealth platforms using these validated instruments can document the clinical basis for prescribing more rigorously than a brief office visit might allow.

Safety Profile and Alcohol Interaction in Montana Patients

Flibanserin carries a boxed warning for CNS depression and hypotension when combined with alcohol. In the dedicated alcohol interaction study that supported the REMS requirement, 25 percent of women who consumed alcohol within two hours of taking flibanserin experienced hypotension or syncope. The FDA safety communication on flibanserin and alcohol formalized that warning.

Beyond alcohol, sedation is the most common adverse effect, occurring in approximately 11 percent of patients in the Phase 3 trials versus 4 percent on placebo. Nausea occurred in 10 percent versus 4 percent. The FDA prescribing label recommends starting at 100 mg nightly and discontinuing after 8 weeks if no improvement occurs, since non-responders at 8 weeks are unlikely to benefit with continued use.

Drug interactions beyond alcohol include CNS depressants (benzodiazepines, sleep aids, opioids), which can amplify sedation. Montana's high rates of prescription opioid use, documented in CDC opioid surveillance data, make this interaction particularly relevant in clinical practice. Prescribers in Montana should conduct a thorough medication reconciliation before initiating flibanserin, with particular attention to concurrent opioid or benzodiazepine prescriptions.

A pharmacokinetic study published in Clinical Pharmacology and Therapeutics confirmed that coadministration of flibanserin with fluconazole (a common antifungal used to treat vaginal candidiasis) increased flibanserin AUC by approximately 7-fold, substantially increasing hypotension risk. Given that vaginal candidiasis is common in reproductive-age women, this interaction is clinically frequent and warrants a specific prescribing check.

Montana-Specific Access Summary

Montana patients seeking flibanserin face a straightforward decision tree based on insurance status.

Commercially insured patients should first confirm formulary status with their specific plan. If covered, the Sprout co-pay card limits cost to $75 per month. If not covered or if prior authorization is denied, compounded flibanserin via a licensed 503A pharmacy at $40 to $120 per month is the next step. The American Society for Reproductive Medicine's 2021 guidance on HSDD supports compounded alternatives when FDA-approved products are financially inaccessible, provided quality sourcing is verified.

Montana Medicaid patients have no formulary pathway to brand Addyi. Compounded flibanserin through a 503A pharmacy, paid out-of-pocket, is the primary option. The Sprout PAP may apply for uninsured or underinsured patients whose income is at or below 400 percent FPL.

Uninsured cash-pay patients face the full $880 list price for brand Addyi unless they access the PAP, GoodRx coupons, or compounding. Compounding is the most cost-effective legal path, typically saving $760 to $840 per month compared with the list price.

Telehealth access statewide removes the barrier of geographic distance in Montana. A provider REMS-certified and licensed in Montana can conduct the full evaluation, diagnosis documentation, and counseling in a single 30-to-45-minute synchronous video visit. ATA (American Telemedicine Association) guidelines on sexual health telehealth confirm that synchronous video evaluation is sufficient for HSDD diagnosis in the absence of suspected organic pathology requiring pelvic examination.

Prescribers in Montana who are not yet REMS-certified can complete the Sprout REMS training at https://www.addyirems.com in under 30 minutes. Certification is required before the first prescription is sent to any pharmacy, compounding or retail. Without REMS certification, retail pharmacies will not dispense brand Addyi, and responsible compounding pharmacies typically require evidence of prescriber REMS compliance as well.

The average retail pharmacy in Billings, Missoula, or Great Falls will stock or order brand Addyi within 24 to 48 hours if a REMS-compliant prescription is presented. Rural pharmacies in counties such as Daniels, Garfield, or Petroleum may not routinely stock it, making mail-order or telehealth-connected compounding pharmacy arrangements more reliable for patients outside urban centers.